Sonnet BioTherapeutics Holdings, Inc. (SONN) NASDAQ
1.26
-1.84(-59.35%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Sonnet BioTherapeutics Holdings, Inc.
Address
100 Overlook Center
Princeton, NJ 08540
United States of America (the)
Phone
609-375-2227
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
October 31, 2006
Key Executives
| Name | Title | Pay | Year Born |
| Raghu Rao | Interim Chief Executive Officer & Director | 116,500 | 1963 |
| Donald J. Griffith | Chief Financial Officer & Director | 90,256 | 1949 |
| John K. Cini | Chief Scientific Officer & Co-Founder | 397,750 | 1953 |
| Gael Hedou | Chief Operating Officer | 0 | 1972 |
| Richard T. Kenney | Chief Medical Officer | 0 | 1958 |
| Stephen J. McAndrew | President & Chief Business Officer | 0 | 1954 |
| Manuel Dafonseca | Head of Clinical Operations | 0 | N/A |
| Susan Dexter | Chief Technical Officer | 0 | 1955 |
Description
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
